CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans." …
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Please stop falling this ridiculous trap, intentional or otherwise, it is not good
November 27, 2025 - - Latest News -
MSD to bring vaccine distribution back in-house after 40-year partnership with CSL Seqirus
November 27, 2025 - - Latest News -
Pharmac announces 90-day dispensed quantities of HIV medicines
November 27, 2025 - - Latest News -
Landmark report warns Australia’s hospital pharmacy system is at an 'inflection point'
November 27, 2025 - - Latest News -
Australia releases first national estimate of women living with metastatic breast cancer
November 27, 2025 - - Latest News -
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 - - Australian Biotech -
Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership
November 27, 2025 - - Latest News